Skip to content

HESA-A :: Dr A.Ahmadi\\\'s Blog

Narrow screen resolution Wide screen resolution Increase font size Decrease font size Default font size default color
Home arrow Papers arrow Animal Study arrow HESA-A: Bright prospect for prevention and treatment of malignancies
HESA-A: Bright prospect for prevention and treatment of malignancies PDF  | Print |  E-mail

 

HESA-A: Bright prospect for prevention and treatment of malignancies

AHMADI A1, MOHAGHEGHI MA1, MOTEDAYEN MH2, TOUDE-DEHGHAN F2, SHARIF TABRIZI A1,

1Institute of cancer, Tehran University of Medical Sciences, Tehran, Iran
2 Razi Institute, Karaj, Tehran, Iran

Background: Cancer is one of the leading causes of death in the world, particularly in developing countries that represents a tremendous burden on patients, families and societies. More than 70% of all cancer deaths occur in low and middle income countries, where resources available for prevention, diagnosis and treatment of cancer are limited or nonexistent.

 

 

The effect of different types of drugs on quality of life and survival of end-stage cancer patients has been investigated, however many side effects of these drugs limited their usage. HESA-A is a compound of natural origin, consisting of rare elements and organic materials, which in several animal and cellular studies have shown powerful anticancer effects and less toxicity on normal cells. The aim of the present study was to investigate the efficacy and safety of HESA-A in the prevention and treatment of Osteosarcoma as a lethal malignancy entire the world.

Methods: In an experimental study, 40 rabbits were randomly allocated to one of two groups of administered HESA-A (study group) and placebo (control group) for 10 days. After this time, carcinogen agent was inserted under the periost for Osteosarcoma formation and bone radiography and magnetic resonance imaging were performed after three months. Also, cases were followed for 6 months.

Results: In study group, among 20 rabbits, pathological bone changes were not detected in 16 cases and after 6 months following-up, all cases were alive and no changes in their appetite and weight were observed. Besides, in placebo group, all cases suffered from Osteosarcoma. In the second stage, control cases were divided into two groups (10 rabbits were treated with HESA-A and 10 cases as non-treated group) and followed-up for 6 months. All non-treated cases were died, whereas treated cases were survived and their appetite and weight were improved.

Conclusion: This study proved the preventive and curative effects of HESA-A on Osteosarcoma and create a bright prospect for the future in the treatment of cancers.

Keywords: Prevention, HESA-A,

Word count: This abstract including the title, authors’ names and affiliations has 1969 characters without spaces

Address of the presenting author (including valid fax number and email):

Presenting author: Amrollah Ahmadi, Dr, MD

Institution: Institute of cancer, Tehran University of Medical Sciences, Tehran, Iran

Address: Emam Khomeini hospital, Dr Gharib Avenue, Tehran, Iran

Tel (work):+9821 66940021

Fax (work): +9821 66933399

Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

 


http://preventionportal.aacrjournals.org/misc/08Prevention_PosterSessionA.pdf

 
< Prev   Next >